Home/Frantz Viral Therapeutics/Mark G. Frantz

MG

Mark G. Frantz

Chairman and CEO

Frantz Viral Therapeutics

Therapeutic Areas

Infectious Disease Oncology

Frantz Viral Therapeutics Pipeline

Drug	Indication	Phase
Artesunate Vaginal Insert	Cervical High-Grade Squamous Intraepithelial Lesion (HSIL)	Phase 2B
Artesunate Ointment	Vulvar High-Grade Squamous Intraepithelial Lesion (HSIL)	Phase 2B
Artesunate Anal Suppository	Anal High-Grade Squamous Intraepithelial Lesion (HSIL) in HIV-negative patients	Phase 2B

Leadership Team at Frantz Viral Therapeutics

Mihaela Plesa, BA, CCRP

Director, Clinical Research Programs

C. Richard Schlegel, MD, PhD

Scientific Advisor / Inventor

Cornelia L. Trimble, MD

Scientific Advisor / Global PI for Cervical & Vulvar Trials

View full Frantz Viral Therapeutics profile